Compare Citius Pharmaceuticals Inc (CTXR) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Redwire Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Redwire Corporation trades at $9.92 (market cap $2.44B). The key difference: Redwire Corporation is far larger — about 179.1× Citius Pharmaceuticals Inc's market cap, and Redwire Corporation is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Redwire Corporation for 18 Days on average.
| CTXR | RDW | |
|---|---|---|
Market Cap | $13.62M | $2.44B |
Volume | 132,438 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $1.82 | $25.90 |
52-Week Low | $0.48 | $5.06 |
Typical Hold Time | 16 Days | 18 Days |
Enterprise Value | $3.79M | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Redwire Corporation (RDW) trades at $10.24, down 3.58% today, with bearish technical signals despite strong analyst support. The company shows robust revenue growth with $335 million in 2025 and projected $426 million in 2026, though profitability remains challenged with negative net margins. Recent Space Force contract wins and partnerships position RDW in the expanding space infrastructure market, but cash flow concerns persist with negative operating cash flow.
RDW presents a high-risk growth opportunity with 80% analyst buy ratings and a $14.88 consensus target offering 45% upside. However, persistent losses, negative cash flow, and dependence on SpaceX's Starship success create significant volatility. The stock suits aggressive investors betting on space infrastructure growth despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
